Richard B.M. Schasfoort (1959) graduated in 1984 as a biotechnology major from the University of Groningen. He defended his PhD thesis for a new approach to biosensor operation in 1989. He is founder of the company IBIS Technologies BV after selling his shares of Bio-intermediair BV in 1996. He developed at IBIS Technologies the Surface Plasmon Resonance imaging (SPRi) platform. In 2002, Richard started the Biochip group at the University of Twente after receiving the VIDI grant from NWO. He is co-author of > 100 peer reviewed papers and editor of the two Handbooks of Surface Plasmon Resonance (2008 and 2017). In the chair Medical Cell BioPhysics of Prof. Leon Terstappen, he investigates single cell binding and secretion fingerprinting of cancer cells. Since the Corona outbreak in March 2020, he changed his focus to antibody profiling using SPRi of patients with COVID19 and cooperated with the hospital Medical Spectrum Twente/Medlon. Triggered by cumbersome analyzes with COVID-19 patients, the focus is currently on developing a device with which the concentration and affinity of antibodies can be measured simultaneously in a plug & play manner.